It is in such a framework that we tested the clinical relevance of this previously developed metabolic score so as to prognosticate the clinical outcomes in a new and multicenter cohort of patients with advanced NSCLC with a PD-L1 TPS of at least 50%, treated with first-line pembrolizumab. The gene discussed is CD274; the disease is non-small cell lung carcinoma.